PERSPECTA

News from every angle

← Back to headlines

Halozyme (HALO) Stock Rated Buy on Strong Royalty Growth

Halozyme Therapeutics (HALO) has received a 'Buy' rating, driven by expectations of strong royalty growth.

2 May, 17:51 — 2 May, 17:51
PostShare

Sources

Showing 1 of 1 sources
YahooMostly Factual96d ago

Halozyme (HALO) Rated Buy on Strong Royalty Growth

Read full article →

Related Stories

Problems with Access to Drug Programs and Modern Therapies in Poland

25m ago

Cyclist Dies in Hospital Following Severe Accident in Slovenia

41m ago

Study Links C-Sections to Reduced Chances of Future Pregnancy

41m ago

Dermatologist Warns Against Accutane 'Beauty-Hype'

48m ago